INT11049

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.60
First Reported 1992
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 3.73
Pain Relevance 0.76

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (IL2RB) plasma membrane (IL2RB) protein complex assembly (IL2RB)
Anatomy Link Frequency
mononuclear cells 2
blood 1
IL2RB (Homo sapiens)
Pain Link Frequency Relevance Heat
Infliximab 62 98.56 Very High Very High Very High
palliative 2 98.32 Very High Very High Very High
cytokine 7 96.72 Very High Very High Very High
headache 3 75.96 Quite High
rheumatoid arthritis 67 73.76 Quite High
Percutaneous transluminal coronary angioplasty 12 50.00 Quite Low
Angina 6 50.00 Quite Low
Potency 1 25.16 Quite Low
tolerance 1 21.24 Low Low
Paracetamol 3 7.68 Low Low
Disease Link Frequency Relevance Heat
Cancer 16 99.68 Very High Very High Very High
Metastasis 4 96.92 Very High Very High Very High
Lymphadenopathy 1 93.48 High High
Mycosis Fungoides 12 90.64 High High
Lymphatic System Cancer 39 90.56 High High
Disease 45 86.00 High High
Lymphocytosis 1 85.16 High High
Lumbar Puncture Related Headaches 1 80.44 Quite High
Headache 2 75.96 Quite High
Toxicity 5 75.04 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Serum levels of Interleukin-2 receptor were elevated during the period of tumour regression but concentrations of other cytokines were normal.
Gene_expression (levels) of Interleukin-2 receptor associated with cancer and cytokine
1) Confidence 0.60 Published 1994 Journal Ir J Med Sci Section Abstract Doc Link 7529223 Disease Relevance 0.73 Pain Relevance 0.22
Interestingly, one of the predictor genes overexpressed in non-responders, IL2RB, has been also found to be significantly overexpressed in peripheral mononuclear cells of infliximab non-responders at baseline [32].
Gene_expression (overexpressed) of IL2RB in mononuclear cells associated with infliximab
2) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2762038 Disease Relevance 0.36 Pain Relevance 0.19
Interestingly, one of the predictor genes overexpressed in non-responders, IL2RB, has been also found to be significantly overexpressed in peripheral mononuclear cells of infliximab non-responders at baseline [32].
Gene_expression (overexpressed) of IL2RB in mononuclear cells associated with infliximab
3) Confidence 0.37 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2762038 Disease Relevance 0.36 Pain Relevance 0.20
There was no obvious correlation with the expression of CD122 or CD132.25
Gene_expression (expression) of CD122
4) Confidence 0.28 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004568 Disease Relevance 1.50 Pain Relevance 0
There was a dose-related increase in the number of peripheral blood lymphocytes expressing the T-cell activation antigen CD69 (Leu 23), but no changes were seen in CD25 (interleukin 2 receptor) expression, and no changes were observed in the serum levels of the soluble interleukin 2 receptor.
Gene_expression (expression) of interleukin 2 receptor in blood
5) Confidence 0.17 Published 1992 Journal Cancer Res. Section Abstract Doc Link 1533172 Disease Relevance 0.79 Pain Relevance 0.15
Two groups of patients were detected: group A, 11 patients who had high levels of soluble interleukin-2 receptor (sIL-2R) before PTCA that decreased toward normal during the follow-up period in most of them; and group B, 13 patients who did not have elevated sIL-2R levels before PTCA and in whom sIL-2R levels did not change after the procedure.
Gene_expression (levels) of sIL-2R
6) Confidence 0.09 Published 1995 Journal Circulation Section Body Doc Link 7805203 Disease Relevance 0 Pain Relevance 0
Two groups of patients were detected: group A, 11 patients who had high levels of soluble interleukin-2 receptor (sIL-2R) before PTCA that decreased toward normal during the follow-up period in most of them; and group B, 13 patients who did not have elevated sIL-2R levels before PTCA and in whom sIL-2R levels did not change after the procedure.
Gene_expression (levels) of interleukin-2 receptor
7) Confidence 0.09 Published 1995 Journal Circulation Section Body Doc Link 7805203 Disease Relevance 0 Pain Relevance 0
Two groups of patients were detected: group A, 11 patients who had high levels of soluble interleukin-2 receptor (sIL-2R) before PTCA that decreased toward normal during the follow-up period in most of them; and group B, 13 patients who did not have elevated sIL-2R levels before PTCA and in whom sIL-2R levels did not change after the procedure.
Gene_expression (levels) of sIL-2R
8) Confidence 0.09 Published 1995 Journal Circulation Section Body Doc Link 7805203 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox